摘要
目的:探索对氧磷酶1(PON-1)基因Gln/Arg192多态性与氯吡格雷抵抗(CR)发生的相关性。方法:采用病例-对照研究的方法,共入选260例接受冠状动脉支架安置(PCI)术并服用氯吡格雷抗血小板治疗的冠心病人作为研究对象,检测二磷酸腺苷(ADP)诱导的最大血小板聚集率,服用300 mg氯吡格雷24 h后最大血小板聚集较基线值下降<10%定义为氯吡格雷抵抗(CR)。根据血小板聚集率检测结果将入选人群分为CR组(n=54)和非氯吡格雷抵抗(NCR)组(n=206)。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法测定PON-1基因Gln/Arg192基因多态性,分析PON-1基因Gln/Arg192多态性与CR发生的相关性。结果:氯吡格雷抵抗发生率为20.8%。PON-1基因Gln/Arg192基因型分布频率符合Hardy-Weinberg平衡定律。RR、QR、QQ基因型频率在CR组分别为38.9%、50.0%、11.1%,而在NCR组分别为30.6%、57.3%、12.1%,基因型频率分布差异在两组间无统计学意义(P>0.05);R、Q等位基因频率在两组间分别为:69.4%、65.3%和30.6%、34.7%,等位基因频率分布差异在两组间亦无统计学意义(P>0.05)。结论:PON-1基因Gln/Arg192多态性与CR的发生无相关性。
Objective： To investigate the correlation between PON-I （Paraoxonase-1） gene Gln/Arg 192 polymorphism to the occurrence and clopidogrel resistance （CR）. Methods： A case-control method was employed. A total of 260 cases of thoracic receiving clopldogrel antithrombotic treatment from coronary heart disease （CHD） from TianJin hospital for PCI were enrolled. The difference between baseline and maximum platelet aggregation below 10% after the use of clopidogrel 300 mg after 24 h was defined as CR. Accordingly, all the enrolled 260 patients were then divided into CR group （n=54） and non-CR （NCR） group （n=206）. PCR-RFLP was executed to determine the genotypes and the allele frequencies of PON-1 gene Gln/Arg192. Results： The incidence of clopidogrel resistance was 20.8%. The genotype frequencies in Gln/Arg192 of PON-1 gene conformed well to the Hardy-Weinberg equilibrium in both CR group and NCR group. Three frequencies of genotype RR, QR and QQ were 38.9%, 50.0%, 11.1% in CR group, and 30.6%, 57.3%, 12.1%in NCR groups, respectively. No significant difference in genotype and allele frequency was found between CR group and NCR group （P=-0.507 and P=0.208, respectively）. Conclusion： This research shows no correlation exists between PON-1 gene Gln/Arg192 polymorphism and clopidogrel resistance in patients with CHD.
出处
《天津医科大学学报》
2014年第1期18-20,共3页
Journal of Tianjin Medical University
